India's antivenom is made against four snakes. There are far more than four snakes.

Snakebite kills more people in India than in any other country — around 58,000 a year by the most careful mortality estimates, the great majority of them agricultural workers, and the great majority during the monsoon months. This is not a disease without a treatment. Antivenom exists, it works, and in government hospitals it is generally free. And yet people who reach a hospital in time still die, and a large part of the reason lies in something most people never think about: how the antivenom in the fridge was manufactured, and which snakes it was made against.

Antivenom is an antibody, farmed

The method has barely changed in over a century. Venom is milked from snakes, and small, escalating doses are injected into a large animal — horses, in India. The horse mounts an immune response and produces antibodies against the venom proteins. Its plasma is then collected, and the antibodies are purified and enzymatically trimmed into fragments that keep the binding ability while reducing the risk of a reaction in the patient.

Two consequences follow immediately from that description, and they explain most of what goes wrong.

First, antivenom is specific to the venom it was raised against. It is not a general antidote. Antibodies recognise particular molecular shapes, and a venom protein that was not in the immunising mixture will not be neutralised well, or at all.

Second, it is a foreign animal protein injected into a human, which is why reactions are common and why antivenom is given under supervision with adrenaline at hand, never at a village clinic without the means to manage anaphylaxis.

The Big Four problem

Indian polyvalent antivenom is raised against four species: the spectacled cobra, the common krait, Russell's viper and the saw-scaled viper. They are called the Big Four because they were judged to cause the overwhelming majority of serious envenoming, and for a national product with a single formulation, four was a reasonable place to start.

The difficulty is that the four are not the only snakes that bite people. Bites from the hump-nosed pit viper, the king cobra, the banded krait and several regionally important vipers and kraits are treated with a product that was never raised against their venom. Clinicians in those regions have reported exactly what the biology predicts: patients who deteriorate despite receiving vial after vial.

Then there is variation within the Big Four. Venom composition differs by geography, by age of the snake, sometimes by season. A Russell's viper in Rajasthan and a Russell's viper in Kerala do not produce identical venom. Historically, most venom used for Indian antivenom production has come from a small number of collection sites in the south, so the product is best matched to snakes from those populations and demonstrably less effective against the same species elsewhere in the country. The vial is not weak; it is aimed slightly to one side of the target.

This is why regional venom collection, region-specific products, and simple studies comparing antivenom performance across states are not academic refinements. They are the difference between a treatment that works where a patient lives and one that works where the horses were immunised.

A vial of antivenom is a set of antibodies against particular molecules from particular snakes in a particular place. Everything that limits it follows from that one sentence.

Two very different kinds of poisoning

Bedside management turns on which broad class of venom is involved, and the two present nothing alike.

Neurotoxic envenoming — cobras and kraits — blocks transmission at the junction between nerve and muscle. The patient develops drooping eyelids, double vision, difficulty swallowing, and then weakness of the muscles used to breathe. Death is by respiratory failure, which also means that a patient kept ventilated can survive while the body clears the toxin.

The krait deserves separate mention because it kills quietly. Its bite is often nearly painless, frequently happens at night to someone sleeping on the floor, and may leave no impressive mark. People go back to sleep with abdominal pain and are found in the morning unable to breathe. Where a cobra bite is a dramatic event nobody misses, a krait bite is routinely mistaken for something else, and that misclassification is lethal. The neurotoxins also differ mechanically: cobra toxins mostly sit on the receptor and can often be countered with drugs that raise acetylcholine, while krait toxins damage the nerve terminal itself, so the same drug helps far less and ventilation matters more.

Haemotoxic envenoming — Russell's viper and the saw-scaled viper — attacks blood and tissue. It consumes clotting factors until the blood will not clot at all, damages capillaries, destroys muscle locally, and in Russell's viper bites frequently injures the kidneys, sometimes leaving survivors on dialysis. Local swelling and pain can be severe, but the dangerous parts are systemic and invisible.

The cheapest useful test in Indian medicine

Distinguishing an envenomed patient from a frightened one matters, because antivenom carries real risk and should not be given for a bite that did not inject venom — and "dry bites", where no venom is delivered, are common.

For viper bites the standard tool is the 20-minute whole blood clotting test: a few millilitres of the patient's blood in a clean, dry glass tube, left undisturbed for twenty minutes, then tipped. Blood that has not clotted is evidence of venom-induced consumption coagulopathy and an indication for antivenom. It needs no reagents, no electricity and no laboratory, it can be repeated every six hours to judge whether more antivenom is needed, and in much of rural India it remains the most useful diagnostic available. Its weaknesses are worth knowing too — it says nothing about neurotoxic bites, and a plastic tube or a shaken sample can give the wrong answer.

The first aid that kills

Much of what is done at the scene actively increases harm.

Tight tourniquets are the most damaging. They do not reliably stop venom spreading, they concentrate tissue-destroying venom in a limb, and when released after a long delay they can flood the circulation at once. Limbs have been lost to the tourniquet rather than the snake. Cutting or sucking the wound introduces infection and worsens bleeding in a patient who may already have no clotting function. Ice, chilli, kerosene, herbal poultices and electric shocks do nothing useful. Time spent with a traditional healer is the single most consistent factor in Indian case series of deaths.

What helps is unglamorous: reassure the patient, keep them still, immobilise the bitten limb in a splint at roughly heart level, remove rings and bangles before swelling starts, and move them to a hospital that stocks antivenom — lying still in a vehicle, not walking. Photograph the snake only if it can be done from a safe distance and without delay; identification is useful, catching the snake is not.

Prevention is more effective than any of this, and equally unglamorous: footwear in fields, a torch at night, sleeping on a cot rather than the floor, and a mosquito net tucked in, which is a genuinely effective krait barrier.

What could change the picture

Antivenom made in horses is a nineteenth-century technology that has saved millions of lives and is finally being reconsidered. Recombinant approaches aim to replace animal plasma with defined mixtures of human or humanised monoclonal antibodies chosen to neutralise the toxin families that matter, which would remove batch variability and much of the reaction risk. Broadly neutralising antibodies against conserved toxin families could, in principle, cover species a Big Four product misses entirely.

A second line is chemically different: small-molecule inhibitors of the main venom enzyme families. These are stable at room temperature, potentially oral, and could in principle be given in a village or an ambulance to buy the hours that currently decide outcomes — the first drug given in the field rather than the hospital.

Policy is moving too. The WHO classified snakebite envenoming as a neglected tropical disease in 2017 and set a target of halving deaths by 2030, and India launched a National Action Plan for prevention and control in 2024, with states asked to make snakebite a notifiable disease. Notification matters more than it sounds: a great deal of the mortality has historically been invisible in official statistics because most deaths happen at home, and a problem that is not counted is not funded.

Why it matters for students and researchers

Snakebite is an unusually good example of a problem where the science that would help most is not exotic. Regional venom variation studies, comparative neutralisation testing of marketed antivenoms against local venoms, careful clinical case series, and work on dosing — how many vials, how often, and when to stop — are all within reach of Indian medical colleges and university laboratories, and all of them are under-published relative to a burden this size. The pharmacology also reaches well beyond envenoming: venoms are libraries of highly selective molecules acting on ion channels, receptors and the clotting cascade, and several established drugs began as venom components.

That span — toxins, their mechanisms, their measurement and their antidotes — is the ground covered by the International Journal of Toxins and Toxics (ISSN 3048-507X), a peer-reviewed open-access journal launched in 2024 publishing across toxicology. For medical, pharmacy and life sciences students in a country carrying the world's largest snakebite burden, it is worth knowing that the most useful contribution here may be a careful local dataset rather than a new molecule.

Frequently asked questions

Why does antivenom sometimes not work?

Because antivenom only neutralises venom proteins it was raised against. India's polyvalent product is made against four species, so bites from other snakes respond poorly, and venom composition also varies geographically within a species, making the product less effective far from where the venom was collected.

What are the Big Four snakes in India?

The spectacled cobra, the common krait, Russell's viper and the saw-scaled viper. Indian polyvalent antivenom is raised against these four because they were judged to cause most serious envenoming.

What is the 20-minute whole blood clotting test?

A bedside test in which a few millilitres of blood are left undisturbed in a clean, dry glass tube for twenty minutes. If the blood has not clotted, it indicates venom-induced coagulopathy from a viper bite and the need for antivenom. It requires no laboratory and can be repeated to guide further doses.

Should a tourniquet be applied after a snakebite?

No. Tight tourniquets do not reliably prevent venom spread, concentrate tissue-destroying venom in the limb, and can cause limb loss. The bitten limb should be immobilised in a splint and the patient moved to hospital while keeping still.

Why are krait bites so dangerous?

Because they are easily missed. The bite is often almost painless, usually occurs at night to someone sleeping on the floor, and may leave little visible mark, so the patient may sleep on with abdominal pain and be found in respiratory failure hours later.